• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • BioAsia 2023 to be held in February 24-26 in Telangana, India
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian?
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE
  • Event: Australia’s biggest week in biotech kicks off in Perth
  • $3 trillion growth reported for biotech sector in USA
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect”
  • Vaccination, Rising Deaths, And The False Narrative
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    July 26, 2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»SARS- CoV2 & COVID-19 Updates»Editorial: COVAXIN- How the only Indian indigenous COVID vaccine of International repute is lagging in world’s race

Editorial: COVAXIN- How the only Indian indigenous COVID vaccine of International repute is lagging in world’s race

0
By Biotech Express on May 23, 2021 SARS- CoV2 & COVID-19 Updates

Kamal Pratap Singh

Pfizer eyes $26B in COVID-19 vaccine sales for the year 2021, with $3.5B (360 crore Rs) already in the bag. Moderna has predicted output of up to 1 billion doses this year. Adar Poonawalla on May 1 announced that the Serum Institute would be able to raise its monthly output to 100 million (10 crore) doses by July. India approved Russian made Sputnik V also, and is also planning to approve vaccines made by Pfizer, Moderna, Johnson & Johnson and others.

Pfizer is making 300 crore doses (3 billion) whereas Indian vaccine manufacturer consortium of Bharat Biotech will make only 90 crore doses till the end of 2021.

The finance ministry approved ₹3,000 crore for Pune-based SII which is manufacturing the AstraZeneca’s COVID-19 vaccine Covishield but granted ₹1567.50 crores to Hyderabad-based Bharat Biotech for boosting the production of indigenous Covaxin.

India recently set the milestone of vaccinating more than 180 million (18 crore) people.

Centre’s statement that India will produce over 216 crore vaccine doses between August and December represents an ambitious scaling up of manufacturing capacity of India. Current workhorses Covishield and Covaxin will yield 75 crore and 55 crore doses respectively (around 50%), while others including Sputnik V and vaccines under trial from Novavax, Zydus Cadila, Biological E and Bharat Biotech’s nasal vaccine will contribute the rest.

COVAXIN®, India’s only indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) high containment facility. The vaccine is developed using Whole-Virion Inactivated Vero Cell derived platform technology. Inactivated vaccines do not replicate and are therefore unlikely to revert and cause pathological effects. They contain dead virus, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection.

Conventionally, inactivated vaccines have been around for decades and are found safest. Numerous vaccines for diseases such as Seasonal Influenza, Polio, Pertussis, Rabies, and Japanese Encephalitis use the same technology to develop inactivated vaccines with a safe track record. It is thus the well-established, and time-tested platform in the world of vaccine technology.

“Manufacturing scale-up has been carried out in a stepwise manner across multiple facilities in Hyderabad and Bengaluru but still it is limited to 700 million (70 crore) doses…,” said the company on April 20th, 2021, which had in January pegged the capacity at 200 million doses a year. Bharat Biotech CMD Krishna Ella at an event in April 2021 said that the company will produce 30 million (3 crore) doses of Covaxin next month (May) against around 20 million (2 crore) doses this month (April) and 15 million in the last month (March). He said that the company expects to reach a production capacity of up to 700 million doses per annum by July-August 2022.

The Union health ministry said the government has paid an advance of ₹1,699.50 crore, after deducting tax at source, to Serum Institute for 110 million (11 crore) doses of Covishield, as well as ₹772.50 crore to Bharat Biotech for 50 million (5 crore) doses of Covaxin. Both payments were made on 28 April.

On May 10, union aviation minister Hardeep Singh Puri has said advance orders for May, June and July have been placed. Puri said the central government has placed advance orders with SII, buying 5.6 crore vaccines worth Rs 1,176 crore through PM Care fund. To Bharat Biotech, he said the Centre has placed orders for 1 crore vaccines worth Rs 216.83 crore through PM Cares; and 5 crore doses on April 22 and 2 crore on May 10 by the health ministry.

Cumulatively, Indian vaccine manufacturers, including SII, Bharat Biotech, Panacea Biotech, Sanofi’s Shanta Biotech, Biological E, Hester Biosciences and Zydus Cadila, have an installed capacity to manufacture 8.2 billion doses of different vaccines per year out of which companies have already planned to give 5.4 billion covid vaccine doses in a year.

If required, total vaccine production capacity can be tweaked to manufacture COVID-19 vaccines. Besides vaccinating every citizen of the country, it can be used to supply vaccines to other countries of the world.

Points to consider while deciding manufacturing and expansion capacities of Bharat Biotech
– Only COVAXIN is indigenous and safe vaccine which has been developed in India
– Bharat Biotech has world class manufacturing expertise approved by USFDA, KFDA and WHO
– Demonstrating capabilities of world’s first: Eco-friendly recombinant Hepatitis-B vaccine (free of cesium chloride and Thiomersal), Rotavirus vaccine from a naturally attenuated strain and Typhoid Conjugate vaccine.
– Among the first in India to develop vaccines for viral diseases like Chikungunya and Zika.
– Bharat Biotech produces largest number of different kind of vaccines.
– Pfizer, the largest contender of COVID-19 vaccine has very stringent storage conditions which can result in unnecessary loss of doses.
– It is effective against emerging mutants.

Recently, the Centre has provided financial assistance in the form of grant of Rs 220 crore to vaccine manufacturers to boost the production of Bharat Biotech’s COVID-19 vaccine Covaxin, and its production is expected to reach more than 10 crore doses per month by September this year (Table).

Conclusion:
Bharat Biotech is perfect candidate for Atma Nirbhar Bharat vaccine production which has ramp-up production to 500 million (50 crore) doses a year. US’s Pfizer has expected to produce 3 billion vaccines but it can be beaten up if 10 such facilities of Bharat Biotech being built up by govt through a more robust investment in the future indigenous vaccine industry of India. As we calculated it will bring more than 3 billion doses which otherwise a target of Pfizer and at the same time we can vaccinate the whole world with a safe and cost effective COVAXIN through FDA, EU, WHO, CEPI, GAVI, COVAX and other alliances.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian?

Maker of Dolo-650, pandemic’s ‘magic pill’, faces income tax searches and PIL petitions

US Military Doctor Testifies under Oath That She Was ORDERED To ‘Cover up’ COVID Vaccine Injuries

Leave A Reply Cancel Reply

Current Issue – October 2022
Upcoming Event

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • BioAsia 2023 to be held in February 24-26 in Telangana, India January 10, 2023
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt November 10, 2022
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian? November 1, 2022
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE October 31, 2022
  • Event: Australia’s biggest week in biotech kicks off in Perth October 26, 2022
  • $3 trillion growth reported for biotech sector in USA October 25, 2022
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect” September 21, 2022
  • Vaccination, Rising Deaths, And The False Narrative September 20, 2022
  • Guestorial: Genome Mapping Techniques and its Application in Aquaculture September 19, 2022
  • Bombay HC Issues Notice To Bill Gates, Serum Institute, DGCI, Others Over Plea On Alleged ‘Vaccine Death’ September 5, 2022
  • Deaths due Covid-19 vaccines should be compensated by vaccine makers: Expert hope on Kerala HC remark August 21, 2022
  • Maker of Dolo-650, pandemic’s ‘magic pill’, faces income tax searches and PIL petitions August 20, 2022
  • Anthony Fauci, Controversial US Top-doc FINALLY, To Retire By Year-end August 20, 2022
  • SII’s Cervevac: The new DCGI approved vaccine without published clinical trial results August 20, 2022
  • Pitch your Start-up to National/International Venture Capitalists – first ever opportunity provided to Bio-Start-ups by FABA August 19, 2022
  • India’s Clinical Trial Registry might disappear soon and so the history of pharma record August 19, 2022
  • Nearly Half of Pregnant Women in Pfizer Trial Miscarried August 10, 2022
  • Researchers develop Cellulose shoes made by bacteria August 9, 2022
  • Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility August 5, 2022
  • CBI Arrests of CDSCO officials, a Biocon official & Intermediaries in an alleged bribery case exposed Corruption in Govt and Pharma sector July 27, 2022
  • We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO July 26, 2022
  • EVENT HIGHLIGHTS: Genome editing as a novel technology for sustainable development July 24, 2022
  • US Military Doctor Testifies under Oath That She Was ORDERED To ‘Cover up’ COVID Vaccine Injuries July 24, 2022
  • Climatic Effect on Marine Biodiversity and their impact on coral reefs July 23, 2022
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.